QLH12016, an investigational oral AR PROTAC, is being evaluated in combination with novel hormonal agents (NHA) such as abiraterone acetate and enzalutamide for the treatment of advanced prostate cancer. The prostate cancer therapeutics market is projected to grow significantly, driven by increasing incidence rates and advancements in treatment options. The combination therapy approach may provide a competitive edge against existing monotherapies and combinations, particularly in patients who have progressed on standard treatments. Qilu Pharmaceutical Co., Ltd. is positioning itself in a niche segment of the prostate cancer market, which could enhance its portfolio and market share if the trial demonstrates favorable safety and efficacy outcomes. Diligence should focus on the competitive landscape, particularly the performance of existing therapies and emerging candidates in similar indications.